Antitubercular treatment does not prevent constriction in chronic pericardial effusion of undetermined etiology: a randomized trial.

Simple item page
dc.contributor.authorDwivedi, S Ken_US
dc.contributor.authorRastogi, Pen_US
dc.contributor.authorSaran, R Ken_US
dc.contributor.authorNarain, V Sen_US
dc.contributor.authorPuri, V Ken_US
dc.contributor.authorHasan, Men_US
dc.date.accessioned1997-07-01en_US
dc.date.accessioned2009-05-27T04:29:31Z
dc.date.available1997-07-01en_US
dc.date.available2009-05-27T04:29:31Z
dc.date.issued1997-07-01en_US
dc.description.abstractPatients of chronic exudative pericardial effusion are frequently treated with antitubercular treatment on presumptive grounds in developing countries, in a hope to prevent constrictive pericarditis. To assess the impact of antitubercular treatment on development of constrictive pericarditis in chronic large exudative pericarditis effusion of undetermined etiology, 25 patients above 12 years of age, with large pericarditis effusion beyond 12 weeks duration, were randomized in a prospective 2:1 fashion, to receive either 3-drug antitubercular treatment (group A) or placebo (group B) for six months. End points studied were, development of pericardial thickness as diagnosed by CT scan and constrictive pericarditis as diagnosed by cardiac catheterization. Twenty-one patients (14 in group A and 7 in group B) completed the study protocol. In all, five (23.8%) patients developed constrictive pericarditis/pericardial thickening. Histopathological examination of pericardiectomy specimens in over five patients were negative for tubercular pathology. Pericardial effusion resolved completely in another 10 (47.8%) patients. There was no significant difference in both the groups in development of constrictive pericarditis/pericardial thickening (group A: n = 3, 21.4% and group B: n = 2, 29.6%, p = NS). On multivariate analysis, development of constrictive pericarditis/pericardial thickening was associated with recurrent tamponade (p = 0.01), presence of tamponade at admission (p = 0.07) and haemorrhagic pericardial effusion (p = 0.08). Thus, antitubercular treatment does not prevent the development of constrictive pericarditis in patients of large chronic pericardial effusion of undetermined etiology.en_US
dc.description.affiliationDepartment of Cardiology, King Georges Medical College, Lucknow.en_US
dc.identifier.citationDwivedi SK, Rastogi P, Saran RK, Narain VS, Puri VK, Hasan M. Antitubercular treatment does not prevent constriction in chronic pericardial effusion of undetermined etiology: a randomized trial. Indian Heart Journal. 1997 Jul-Aug; 49(4): 411-4en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/5872
dc.language.isoengen_US
dc.source.urihttps://indianheartjournal.comen_US
dc.subject.meshAdulten_US
dc.subject.meshAntitubercular Agents --therapeutic useen_US
dc.subject.meshChronic Diseaseen_US
dc.subject.meshDrug Therapy, Combinationen_US
dc.subject.meshEchocardiographyen_US
dc.subject.meshEthambutol --administration & dosageen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshHumansen_US
dc.subject.meshIncidenceen_US
dc.subject.meshIsoniazid --administration & dosageen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshMultivariate Analysisen_US
dc.subject.meshPericardial Effusion --drug therapyen_US
dc.subject.meshPericarditis, Constrictive --epidemiologyen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshRifampin --administration & dosageen_US
dc.subject.meshTreatment Failureen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleAntitubercular treatment does not prevent constriction in chronic pericardial effusion of undetermined etiology: a randomized trial.en_US
dc.typeClinical Trialen_US
dc.typeJournal Articleen_US
dc.typeRandomized Controlled Trialen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Indian Heart Journal